Gelonghui, April 9 | Cornerstone Pharmaceutical-B (02616.HK) announced that the company was informed by Yang Jianxin, CEO, President of R&D and Executive Director, that it purchased a total of 0.56 million shares on the open market with its own capital from April 2 to April 7, 2025. The purchase price per share ranged from HK$2.26 to HK$3.29. Since becoming CEO in August 2022, Yang Jianxin has purchased a total of 10.359 million shares, with a purchase price of between HK$0.82 and HK$4.60 per share. After purchasing the shares, Yang Jianxin held a total of about 5.46% of the company's total issued share capital at the date of the announcement.
Yang Jianxin told the company that he is full of confidence in the company's future prospects, and that the increase in the company's shares represents his belief in the company's ability to maintain steady operation while achieving rapid growth in a complex and changing market environment, as well as unremitting support for the company's growth and development. Yang Jianxin does not rule out that it may further increase its shares in the Company in due course.
The company's board of directors believes that the increase in the company's shares by its CEO, R&D President and Executive Director reflects Dr. Yang's long-term commitment to the company and confidence in the company's future business prospects.
